Jacob Sands, Jason Timothy Henry, Alexander I. Spira, Daruka Mahadevan, Catherine Belle Meador, Jared Weiss, Abdul Rafeh Naqash, Jennifer A. Chan, Himisha Beltran, Grace H McGregor, Rita Laeufle, Hui Zou. "An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps8128